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ABSTRACT
The clinical benefits of the MammaPrint® signature for breast cancer is well 
documented; however, how these genes are related to cell cycle perturbation have 
not been well determined. Our single-cell transcriptome mapping (algorithm) 
provides details into the fine perturbation of all individual genes during a cell cycle, 
providing a view of the cell-cycle-phase specific landscape of any given human genes. 
Specifically, we identified that 38 out of the 70 (54%) MammaPrint® signature genes 
are perturbated to a specific phase of the cell cycle. The MammaPrint® signature panel 
derived its clinical prognosis power from measuring the cell cycle activity of specific 
breast cancer samples. Such cell cycle phase index of the MammaPrint® signature 
suggested that measurement of the cell cycle index from tumors could be developed 
into a prognosis tool for various types of cancer beyond breast cancer, potentially 
improving therapy through targeting a specific phase of the cell cycle of cancer cells.
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 70), pp: 33290-33301
INTRODUCTION
Breast cancer remains one of the most devastating 
diseases worldwide. Traditionally, estrogen receptor (ER), 
progesterone receptor (PR) and Her2 have been used to 
classify breast cancer into three subtypes: positive for 
hormonal receptors (ER+), Her2+, and triple negative 
(TNBC) without these receptors. While ER+ tumors 
are treated with selective ER modulators or aromatase 
inhibitors and Her2+ tumors are treated with antibodies 
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against this receptor [1], TNBC tumors do not have a 
specific treatment, prompting the search for innovative 
approaches. A genome-wide association study (GWAS) 
revealed the tumor necrosis factor superfamily member 
13B (TNFSF13B) gene, suggesting new target-specific 
therapies [2]. Translation of these transcriptome results to 
clinical practice is underway. The clinical significance of 
a breast-cancer-associated, 70-gene signature panel (a.k.a., 
MammaPrint® signature) was first reported as a clinical 
tool to help refine prognosis in the NEJM fourteen years 
ago [2], as implemented by Agendia BV, Amsterdam, 
The Netherlands for scale-up clinical trials. Initially, van 
‘t Veer and colleagues screened a total of 25,000 genes 
of using microarray technology for supervised clustering 
on mRNA expression of 70 genes and van ‘t Veer et al. 
validated for either a low or high risk of patients. The 
70-genes assay was adopted in the US for clinical practice 
since van ‘t Veer moved to University of California, 
San Francisco. Based on the 70-gene MammaPrint® 
signature, the same group reported a follow-up NEJM 
article, showing that “no chemotherapy led to a 5-year 
rate of survival without distant metastasis that was 1.5% 
lower than the rate with chemotherapy”, with 1550 
patients (23.2%) at high clinical risk and low genomic 
risk for recurrence, out of a randomized Phase 3 study 
with 6693 enrolled early-stage breast cancer patients [3]. 
This suggests that approximately 46% of women at high 
clinical risk may not need chemotherapy. Monitoring the 
MammaPrint® 70-gene signature can guide the treatment. 
However, these genes were selected empirically from 
breast cancer cases through time. It is not clear why these 
genes have predictive power and whether such a panel can 
be applied to other types of cancers. 
Here, we report a new algorithm to cluster genes 
that share the same cell cycle phase (i.e., G0, G1, S, or G2) 
based on a spectrum of single-cell transcriptomes from a 
cell-cycle model system. This algorithm allows cells to 
be sorted into subpopulations of sharing the same cell-
cycle phases. We inferred a possible mechanism by which 
predictive power of MammaPrint® signature predicts its 
clinical outcomes for breast cancer. 
RESULTS
We defined phase-specific, cell-cycle-dependent 
single-cell transcriptomes using the model system - Fucci 
cells, which have fluorescent cell-cycle phase-specific 
indicators. We obtained single-cell transcriptomes from 
these Fucci cells with our microfluidic platform with 
nanoliter reactors [5]. Combining these two technologies 
allowed for the characterization of a cell cycle phase-
specific map using a similarity matrix (algorithm) based 
on known cell cycle genes (GO:0022402). We used this 
algorithm to create a novel cell cycle map of known 
cell cycle genes in the corresponding sequential order 
(Figure 1). As expected, known cell cycle genes had 
expression perturbation profiles that agreed with 
previously reported studies of physical cell lysates. In 
addition to known cell cycle genes, genes indicated by the 
Self-Organizing Map (SOM) analysis were also plotted 
onto the cell cycle map to identify novel candidate cell 
cycle genes, termed cell cycle index.
We applied this algorithm to assess the cell cycle 
activity of the MammaPrint® 70-gene signature [4] to create 
a cell-cycle index for cell-cycle-phase-specific mapping 
as generated from single-cell transcriptomes. In addition 
to the previously reported 15 cell cycle-related genes 
[5, 6], our strategy revealed 23 additional cell cycle-
associated genes among the 70 MammaPrint® genes. 
Among the 23 newly identified cell cycle-related genes, 
we identified 15 genes regulating G1 phase (Figure 2B), 
5 genes regulating S-phase (Figure 2C), and 3 genes 
regulating G2 phase (Figure 2A). More importantly, 
these cell cycle specific genes are associated with clinical 
outcomes, as judged with current database of breast cancer 
patients’ consequences in multiple reports and clinical 
trials, including cancer recurrence (Table 1), cancer 
pathological stage (Table 2), and primary versus metastatic 
disease (Table 3). 
Specifically, nine genes of the 70 MammaPrint® 
genes are regulated in a cell cycle specific pattern at cancer 
recurrence (Table 1), including CCNE2, CENPA, LIN9, 
RUNDC1, BRCA2, CCNB1, CDC25A, CDC25C, and 
CDKN2D. Four of these nine genes, CCNE2, CENPA, 
LIN9, RUNDC1, are newly defined as phase-related 
genes of cell cycle, which can be used as prognostic 
biomarkers for either 3- or 5-year survival with p-Value < 
0.05. In particular, CCNB1 in the cohort of “Recurrence or 
metastasis at 3 years (N = 8 patients)” showed a 3.124-fold 
change (p = 0.002), in the cohort of “No Recurrence or 
metastasis” at 3 years (N = 78 patients)” had a 2.465-fold 
change, in the cohort of “Recurrence or metastasis at 5 years 
(N = 14 patients)” had a 3.124-fold change (p = 0.023), and 
in the cohort of “No Recurrence or metastasis at 5 years 
(N = 68 patients) had a 2.465-fold change (Table 1). In Table 
3, CENPA in Silico analysis of breast cancer biomarkers 
for metastasis vs. primary showed a 2.46-fold change 
(p-Value = 0.031, while CDC25C, a 2.24-fold change, 
p = 0.017. In Table 2, biomarker-governed pathological 
stages consisted of these nine genes, in particular, CCNE2 
showed a 2.073-fold change with p = 0.002; CENPA, 
associated ERBB2/ER/PR negative (211 patients) vs. other 
biomarker status (1,340 patients), a 2.402-fold change, p 
= 4.33E-08, and another cohort, CENPA associated with 
ERBB2/ER/PR negative (39 patients) vs. other biomarker 
status (129 patients), a 3.625-fold change, with p = 5.90E-
04. In a small cohort, BRCA2-expression associated-Grade 
3 (3 patients) vs. -Grade 2 (7 patients) showed a 5.117-fold 
change (p = 0.009), while CDC25A of Grade 3 (3 patients) 
vs. Grade 2 (7 patients) showed a 8.625-fold change 
(p = 9.48E-04) and CDC25A of ERBB2/ER/PR negative 
(39 patients) vs. positive had a 2.324-fold change with 
Oncotarget33292www.oncotarget.com
p = 4.74E-05. CDC25C in Grade 3 (3 patients) vs Grade 2 
(7 patients) showed a 4.042-fold change (p = 0.001) while 
in the cohort of Bloom-Richardson Grade 2 (8 patients) vs. 
of Bloom-Richardson Grade 1 (5 patients), CDC25C had 
a 2.228-fold change with p = 0.008 (Table 2). In summary, 
38 (more than half, 54%) of the 70 MammaPrint® genes are 
involved in cell cycle control; nine of which are associated 
with breast cancer patients.
DISCUSSION
Current commercially available assays include the 
MammaPrint®, OncotypeDX (the 21-gene Recurrence 
Score, with reverse transcriptase PCR (RT-PCR), PAM50/
Prosigna (on the expression of 46 genes using quantitative 
PCR (qPCR), by NanoString Technologies, Seattle, WA), 
Endopredict (use the expression of 8 cancer-related and 
3 reference genes determined with RT-PCR, by Myriad 
Genetics Inc, Salt Lake City, UT), of which four criteria is 
considered: “assay development and methodology, clinical 
validation, clinical utility and economic value” [7]. 
Although level IA clinical trial results show MammaPrint® 
and OncotypeDX for prognostic information, clinical 
utility studies show a higher reduction in chemotherapy 
was achieved only by OncotypeDX. The inconsistency 
may be derived from inter-tumor and intra-tumor 
heterogeneity as these results were based on assays on 
bulky tumors. We have recently shown that a cancer 
relapse signaling pathway can be detected only in a 
single-cell transcriptome, not in a bulky tumor analysis, 
Figure 1: Sequential perturbations of cell-cycle-specific genes in a single-cell model system. After organizing single-cell 
transcriptomes by similarity into a sequencing order, expression levels of various cell-cycle-specific genes were plotted to visualize the 
sequential perturbation of individual genes during the cell cycle. Cell cycle phases were defined and colored based on the cell cycle 
molecular map. As expected, G0/G1-specific genes had higher expression levels in the G0/G1 phase (A) and G2/M-specific genes had 
high expression levels in the G2/M phase (B). G2/M-specific genes had high expression levels in the G2/M phase and the early G0/G1 
phase (C). Note: the numbers along the outside circle (#1 – 29) represent the cell cycle phase: #1- #15 for G1-phase; #16-#22, S-phase; 
#23-#29, G2/M-phase. The number on the vertical scale radiating from the center represents the level of gene expression with the center 
representing 0, the lowest, scaling up to the outer circle, the highest.
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as bulky tumor transcriptomic analyses obscure the low 
signal of certain biomarkers [8]. We rationalized that 
single-cell transcriptomic analysis can enhance signal-
to-noise ratio over bulky tumor transcriptomic analysis. 
Here, we discovered that a total of 38 genes (23 of them 
were revealed within the present work) measured with 
the MammaPrint® assay are cell cycle regulated. We 
conclude that the MammaPrint® assay would average 
out perturbations in gene expression when applied to a 
mixture of cells and thus remain undetected when using 
bulky tumors. We further illustrate that the advantage 
of our finding would make it possible (1) to attack the 
respective gene products using a combination therapy and 
(2) to deliver the right drugs to cells of the respective cell 
cycle stage.
More specifically, the results of these single-
cell transcriptomes provide details relating to define 
perturbation of critical genes during the cell cycle. 
Such concentrating on cell cycle related genes reveals a 
possible mechanism for the greatest prognostic power 
of MammaPrint®. Our results, which have identified an 
additional 23 cell cycle-related genes, bring the total 
Figure 2: Perturbation of MammaPrint® genes during cell cycle suggests that many MammaPrint® genes are cell cycle 
regulators. With microfluidic devices, transcriptomes of individual cells were arranged by similarity to construct a cell cycle map with 
29 single-cells with each single-cell represented a specific stage of the cell cycle. The distance between cells represent their similarity 
with neighboring cells. The map reveals the stepwise perturbations of all genes during the cell cycle, such as G1-phase, S-phase, and G2-
phase. The mRNA perturbation of majority of MammaPrint® genes was plotted and presented by expression levels. (A) Highly expression 
MammaPrint® gene; (B) medium expression MammaPrint® genes and (C) low expression MammaPrint® genes. Genes at all level of 
expression showed cell-cycle dependent perturbation patterns. These results suggest that majority of MammaPrint® genes are cell cycle 
regulators and MammaPrint® gene panel is a cell cycle index panel.
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Table 1: Breast cancer recurrence governed by cell cycle regulated genes*
Gene name Incidence of patient's recurrence Expression  median
Fold  
change P-value Gene rank Reference
CCNE2 No Recurrence at 3 Years (N = 6) -1.381 0.03 467 (in top 3%) Esserman et al., 2012
 Recurrence at 3 Years (N = 3)  -0.654  Esserman et al., 2012
CENPA 1. No Recurrence at 3 Years (N = 10) –0.44 1.76E-04 20 (in top 1%) Desmedt et al., 2007
 2. Recurrence at 3 Years (N = 3) 1.197   
1. No Recurrence at 5 Years (N = 9) –0.707 2.29E-04   24 (in top 1%)   Desmedt et al., 2007
 2. Recurrence at 5 Years (N = 3) 1.197   
1. Alive at 3 Years (N = 77) –134 0.002 187 (in top 1%) Esserman et al., 2012
 2. Dead at 3 Years (N = 15) –0.355   
1. Alive at 5 Years (N = 21) –1.807 2.12E-04 26 (in top 1%) Esserman et al., 2012
 2. Dead at 5 Years (N = 20) –566   
1. No Recurrence at 3 Years (N = 78) 1.373 0.01 380 (in top 2%) Loi et al., 2007  
 2. Recurrence at 3 Years (N = 8) 2.246   
1. No Recurrence at 5 Years (N = 66) –0.062 0.007  471 (in top 3%)   Loi et al., 2008 
 2. Recurrence at 5 Years (N = 10) 0.604   
LIN9 No Recurrence at 3 Years (N = 69) 0.418 0.009 589 (in top 4%) Esserman et al., 2012
 Recurrence at 3 Years (N = 24) 0.722   
1. No Recurrence at 5 Years (N = 8) 0.594 0.011 924 (in top 5%) Finak et al., 2008
 2. Recurrence at 5 Years (N = 11) 1.149   
RUNDC1  1.442 0.151 5579 TCGA Breast (database)
–1.059 0.52 8666 Radvanyi et al., 2005
  –1.061 0.592 13627 Bittner (database)
BRCA2 Recurrence  at 3 years (N = 4) 0.596 0.014  516 top 3%  Loi et al., 2008 
No Recurrence at 3 years (N = 72) –0.076 Loi et al., 2008 
 Recurrence or metastasis at 5 years (N = 6) 0.639 4.83E-04  87 top 1% Loi et al., 2008 
No Recurrence or metastasis at 5 years (N = 69) –0.09 Loi et al., 2008 
 Recurrence at 5 Years (N = 10) –0.257 0.043  861 top 6% Ma et al., 2003 
No Recurrence at 5 Years (N = 22) –1.602 Ma et al., 2003 
 Recurrence at 3 Years (N = 3) –1.427 0.038  958 top 8% Desmedt et al., 2007
No Recurrence at 3 Years (N = 10) –2.141 Desmedt et al., 2007
CCNB1 Recurrence or metastasis at 3 years (N = 8) 3.124 0.002 103 top 1% Loi et al., 2007  
No Recurrence or metastasis at 3 years (N = 78) 2.465 Loi et al., 2007  
 Recurrence or metastasis at 5 years (N = 14) 3.124 0.023 1306 top 7% Loi et al., 2007  
No Recurrence or metastasis at 5 years (N = 68) 2.465 Loi et al., 2007  
  No Recurrence at 3 Years (N = 71) –0.04 0.018 487 (in top 3%) Loi et al., 2008 
Recurrence at 3 Years (N = 5) 0.853 Loi et al., 2008 
 No Recurrence at 3 Years (N = 10) 1.338 0.046 1130 (in top 9%) Desmedt et al., 2007
Recurrence at 3 Years (N = 3) 2.709 Desmedt et al., 2008
CDC25A No Recurrence at 1 Year (N = 269) –1.985 0.002 312 (in top 3%) Esserman et al., 2012
Recurrence at 1 Year (N = 16) –0.749 Esserman et al., 2012
 No Recurrence at 3 Years (N = 217) –2.08 6.83E-04 532 (in top 5%) Esserman et al., 2012
Recurrence at 3 Years (N = 68) –1.078 Esserman et al., 2012
 1. No Recurrence at 3 Years (N = 10) –2.893 0.002 94 (in top 1%) Esserman et al., 2012
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number of predicative genes to 38, thereby significantly 
improving the clinical value of the MammaPrint® 
panel. We propose that these results can be applied to 
focus potential strategies to create more efficacious, 
targeted combinations of drugs, specifically addressing 
the appropriate cells in the correct cell cycle stage 
[9, 10]. We suggest this cell cycle stage index (i.e., 
mapping out a spectrum of a specific phase of the cell 
cycle for a particular single cell) can be applied in cancer 
treatment (Figure 3) by monitoring subclonal growth 
through determination of switchboard signals (i.e., 
cytokines and chemokines) which may transform cells 
from dormancy to dominating subclones [11]. Clinical 
applications of cocktails of targeting a specific phase of 
the cell cycle can be applied to modulate the subclonal 
evolution for prognosis, thereby guiding the timing of 
therapeutic intervention. The 38-cycle-related genes in 
the MammaPrint® 70-gene panel, as confirmed by clinical 
specimens (Tables 1, 2, 3), shed new light on subclonal 
evolution of common cancer treatment resistance, as certain 
cell-cycle stages, such G0, show resistance to treatment. 
This suggests that management of cell cycle stages can be 
therapeutic effective as it is tumor-subclone-specific, which 
is cell-cycle-dependent (Figure 3). 
Such single-cell knowledge of categorizing distinct 
subpopulations of an organ may serve as a starting point 
to reconstruct the origins for the different subtypes of any 
organ-specific disease [12]. Single-cell identity may serve as 
a resource to map out the defined changes occurring during 
disease onset, potential to improve methods of detection and 
treatment. Next generation sequencing technology enables 
single-cell mRNA sequencing (scRNAseq) to create a 
high-resolution “molecular census of recognition” that was 
previously unseen cellular differences [13]. Isolated from 
prostate tumor and associated cells, for example, Calcinotto 
and colleagues identified two IL-23-regulated proteins 
(STAT3 and RORγ) that support androgen-receptor-
associated tumor growth [14] in myeloid-derived suppressor 
cells (MDSCs) (including monocytes and neutrophils) at 
an immature state [15]. From insights into this immature 
state, novel therapies of either antibody (blocks IL-23) or 
enzalutamide (androgen-receptor inhibitor) were employed 
to shrink the tumors [16]. 
To secure efficacy of cell cycle-based therapy, 
physicians need to track down the spatiotemporal changes 
of each cell within breast tissue at molecular, cellular and 
tissue levels. Technologies (next generation sequencing 
technology, single-cell mRNA sequencing for single-
cell gene signatures, and positioning imaging system 
for biomarkers [17]) can capture the spatiotemporal 
information that defines the cell-by-cell origins of 
breast cancer, in its earliest phases that acquire genetic 
alterations, potential for early cancer detection, leading 
to cancer prevention, slowing cancer progression or early 
management for co-survival with cancer [11], before it 
turns into a life-threatening cancer burden [18]. Such non-
2. Recurrence at 3 Years (N = 3) –0.037 Esserman et al., 2012
CDC25C No Recurrence at 3 Years (N = 10) –0.706 0.002 79 (in top 1%) Loi et al., 2007  
Recurrence at 3 Years (N = 3) –0.12 Loi et al., 2007  
 No Recurrence at 5 Years (N = 9) –0.879 0.002 82 (in top 1%) Desmedt et al., 2007
Recurrence at 5 Years (N = 3) –0.12 Desmedt et al., 2007
 No Recurrence at 3 Years (N = 78) 0.193 0.006 245 (in top 2%) Loi et al., 2007  
Recurrence at 3 Years (N = 8) 0.893 Loi et al., 2008
 No Recurrence at 5 Years (N = 68) 0.138 0.002 118 (in top 1%) Loi et al., 2009
Recurrence at 5 Years (N = 14) 0.893 Loi et al., 2010
 No Recurrence at 3 Years (N = 6) –1.563 0.038 917 (in top 5%) Esserman et al., 2012
Recurrence at 3 Years (N = 5) –0.795 Esserman et al., 2013
CDKN2D No Recurrence at 5 Years (N = 68) 0.405 0.009 584 (in top 3%) Loi et al., 2007  
Recurrence at 5 Years (N = 14) 0.6
 No Recurrence at 3 Years (N = 229) –0.051 0.001   491 (in top 4%)
van de Vijver et al., 
2002 
MammaPrint®  
Recurrence at 3 Years (N = 63) 0.01 MammaPrint 70-gene list
 No Recurrence at 5 Years (N = 68) –0.059 9.53E-04 489 (in top 4%)
van de Vijver et al., 
2002 
MammaPrint®  
 Recurrence at 5 Years (N = 14) 0.006    
*Novel phase-related genes in red on A column.
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invasive imaging-based analysis of spatiotemporal gene-
expression patterns [17] in single cells may shed new light 
onto the developmental processes that lead to “wait-and-
watch” approaches [18], by defining “therapeutic windows” 
[19], with multiple check points of the full spectrum of 
cellular diversity that exists in the human body, in cancer 
initiation, progression and metastasis. 
Cell cycle gene regulation plays a critical role not 
only in repair after tissue injury (e.g., stem cell-mediated 
regeneration), but also in cancer surveillance, and more 
recently has been employed as a tool in immunotherapy-
based “wait-and-watch” approaches to cancer [18, 20]. 
Cell cycle gene regulation is tightly regulated by essential 
kinases such as members of the CDK family and their 
Table 2: Pathological stages of breast cancer governed by biomarkers expression*
Gene name Stage and number of patients
Fold  
change P-value Gene rank Reference
CCNE2 Grade 3 (10) vs Grade 2 (20) 2.073 0.002 149 (in top 1%) MA XJ et al., 2004
CENPA TP53 Mutation (84) vs TP53 Wild Type (557) 1.679 1.82E-16 1 (in top 1%)   Curtis et al., 2012
ERBB2/ER/PR Negative (211) vs another Biomarker Status (1,340) 2.135 7.02E-57 25 (in top 1%)   Curtis et al., 2012
 Stage II (4) vs Stage I (3) 1.706 0.009 139 (in top 1%)   Curtis et al., 2012
ERBB2/ER/PR Negative (39) vs Another Biomarker Status (129) 2.402 4.33E-08 94 (in top 1%) Bittner et al., 2005
 M1+ (5) vs M0 (176) 2.327 1.00E-02 996 (in top 6%) Bittner et al., 2005
N1+ (12) vsN0 (7) 4.343 9.95E-05 12 (in top 1%) Lu et al., 2008
 Grade 3 (4) vs Grade 2 (3) 2.221 8.00E-03 188 (in top 2%) Desmedt et al., 2007
TP53 Mutation (58) vsTP53 Wild Type (189) 1.67 3.94E-13 41 (in top 1%)   Ivshina et al., 2006
 TP53 Mutation (58) vsTP53 Wild Type (189) 1.502 5.17E-04 521 (in top 3%)   Gluck et al., 2012
ERBB2/ER/PR Negative (39) vs other Biomarker Status (129) 2.086 5.80E-04 751 (in top 4%) Richardson et al., 2006
 ERBB2/ER/PR Negative (39) vs other Biomarker Status (129) 3.625 5.90E-04 178 (in top 2%)   Zhao H et al., 2004
LIN9 N1+ (12) vs N0 (7) 1.658 7.86E-04 94 (in top 1%) Lu et al., 2008
ERBB2/ER/PR Negative (39) vs Another Biomarker Status (129) 1.627 1.00E-06 261 (in top 2%) Bittner et al., 2005
 ERBB2/ER/PR Negative (18) vs Another Biomarker Status (19) 1.732 2.96E-04 575 (in top 3%) Richardson et al., 2006
RUNDC1 Grade 3 (3) vs Grade 2 (24) vs Grade 1 (13) 0.038 1023 (in top 6%)   Curtis et al., 2012
Grade 3 (17) vs Grade 2 (3) 1.183 0.044 3511 (in top 19%) Nik-Zainal et al., 2012
BRCA2  Grade 3 (10) vs Grade 2 (20) 2.693 4.13E-06 4 (in top 1%) MA XJ et al., 2004
Dead at 1 Year (7) vs Alive at 1 Year (47) 1.962 3.10E-05 4 (in top 1%) Sorlie et al, 2001
 Dead at 1 Year (12) vs Alive at 1 Year (69) 1.594 0.002 42 (in top 1%) Sorlie et al, 2003
Grade 3 (3) vs Grade 2 (7) 5.117 0.009 752 (in top 6%) Desmedt et al., 2007
CCNB1 ERBB2/ER/PR Negative (39) versus other (129) 1.712 4.28E-05 811 top 5% Bittner et al., 2005
M0 (176) vs M1+ (5) 1.634 0.018 1461 top 8%
 Grade 3 (10) vs Grade 2 (20) 1.782 0.006 299 top2 % MA XJ et al., 2004
N1+ (12) vs N0 (7) 3.198 3.56E-04 47 top 1% Lu et al., 2008
CDC25A Grade 3 (3) vs Grade 2 (7) 8.625 9.48E-04 175 (in top 2%) Desmedt et al., 2007
ERBB2/ER/PR Negative (39) vs positive 2.324 4.74E-05 838 (in top 5%) Bittner et al., 2005
2.452 3.04E-04 40 (in top 1%) Ma XJ et al., 2004
CDC25C Grade 3 (3) vs Grade 2 (7) 4.042 0.001 221 (in top 2%) Desmedt et al., 2007
Bloom-Richardson Grade 2 (8) vs Bloom-Richardson Grade 1 (5) 2.228 0.008 1130 (in top 6%) Lu et al., 2008
 Elston Grade 3 (16) vs Elston Grade 2 (37) vs Elston Grade 1 (17) 1.04E-07 27 (in top 1%) Loi et al., 2007
CDKN2D M1+ (5) vs M0 (176) 1.921 7.76E-04 227 (in top 2%) Bittner et al., 2005
N1+ (16) vs N0 (14) 1.99 0.032 1455 (in top 8%) Bittner et al., 2005
 Grade 3 (10) vs Grade 2 (20) 1.533 0.009 383 (in top 3%) MA XJ et al., 2004
 M1+ (8) vsM1+ (8) 1.503 0.012 921 (in top 5%) Kao KJ et al., 2011
*Novel phase-related genes in red on A column.
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effectors. Monitoring cell cycle activity—including 
phenotyping immune cell and cancer stem cell subsets, 
tracking cell proliferation, and measuring cytokine 
production—can provide insights into the overall status 
of cancer in patients, and identify those cell populations 
which manage to survive cancer treatments. However, 
conventional gene expression profiling, which relies 
on population averaging of millions of heterogenous 
cells (malignant vs. normal cells), cannot realistically be 
expected to detect fine perturbations in gene expression 
that are precisely regulated on both temporal and spatial 
scales. Consequently, expression perturbations of many 
cell-cycle-related genes may remain masked in crude cell 
lysate analysis. The expression patterns of these cell-cycle 
Table 3: Breast cancer biomarkers In Silico analysis: Metastasis vs primary*
Gene name Metastasis vs primary Fold change P-value Gene rank Reference
CCNE2 Metastasis vs primary 1.681 0.058 2249 Bittner Breast database 2005
Metastasis vs primary 1.214 0.307 3190 Weigelt et al., 2003
 Metastasis vs primary –1.423 0.786 12226 Radvanyi et al., 2005
Metastasis vs primary –1.119 0.578 13819 TCGA 2005 database
CENPA Metastasis vs primary 2.464 0.032 168 Weigelt et al., 2003
Metastasis vs primary 1.057 0.131 2895 Haverty Breast
 Metastasis vs primary 1.521 0.096 3298 Bittner Breast database 2005
Metastasis vs primary 1.828 0.155 4115 Radvanyi et al.., 2005
LIN9 Metastasis vs primary 1.445 0.174 5203 Bittner Breast database 2005
Metastasis vs primary –1.085 0.581 9471 Radvanyi et al., 2005
 Metastasis vs primary –1.176 0.825 17493 TCGA 2005 database
RUNDC1 Metastasis vs primary 1.442 0.151 5579 TCGA 2005 database
Metastasis vs primary –1.059 0.52 8666 Radvanyi et al.., 2005
 Metastasis vs primary –1.061 0.592 13627 Bittner Breast database 2005
BRCA2 Metastasis vs primary –1.036 0.55 3551 Sorlie et al, 2003
Metastasis vs primary –1.034 0.61 6852 Weigelt et al., 2003
 Metastasis vs primary 1.09 0.326 8552 Bittner Breast database 2005
Metastasis vs primary –1.531 0.851 13239 Radvanyi et al., 2005
 Metastasis vs primary –1.287 0.699 15588 TCGA 2005 database
CCNB1 Metastasis (9) versus primary (327) 1.506 0.05 2037 top 11% Bittney database 2005
 Metastasis (5) versus primary (103) –1.212 0.748 4538 top 74% Sorlie et al., 2001
Metastasis (6) versus primary (4) –1.313 0.807 8893 top 87% Weigelt et al., 2003
 Metastasis (7) versus primary (47) –1.397 0.703 11075 top 67% Radvanyi et al.., 2005
Metastasis (3) versus primary (529) –1.133 0.687 15399 top 76% TCGA 2005 database
CDC25A Metastasis vs primary 1.673 0.014 828 Bittner Breast database 2005
Metastasis vs primary –1.016 0.518 3417 Sorlie et al, 2003
 Metastasis vs primary 1.098 0.357 3809 Weigelt et al., 2003
Metastasis vs primary 1.488 0.149 4018 Radvanyi et al.., 2005
 Metastasis vs primary –1.407 0.76 16431 TCGA 2005 database
CDC25C Metastasis vs primary 2.248 0.017 932 Bittner Breast database 2005
Metastasis vs primary 1.101 0.1 1140  TCGA Breast 2 database
 Metastasis vs primary 1.618 0.082 593 Weigelt et al., 2003
CDKN2D Metastasis vs primary 1.415 0.01 224 Sorlie et al, 2003
Metastasis vs primary 1.464 0.535 3559 Bittner Breast database 2005
 Metastasis vs primary –1.02  6008 Weigelt et al., 2003
*Novel phase-related genes in red on A column.
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genes as predicted by this algorithm remain to be validated 
in clinical trials for prognosis of other types of cancers. 
Conclusion: With single-cell transcriptome analysis, 
we reveal that the previously unknown predictive power 
of MammaPrint® signature panel arises from the cell cycle 
genes it profiles, and that the expression patterns of these 
cell cycle genes can be used for prognosis of other types 
of cancers.
MATERIALS AND METHODS
Cell culture and single-cell cDNA synthesis
H9 human embryonic stem cells (WA09, WiCell 
Research Institute, Inc.) were maintained with a feeder-
free protocol as previously described [21, 22]. HeLa F. 
(RIKEN Cell Bank RCB2812) cells (Fucci cells) [23] were 
grown under standard conditions and cultured in Advanced 
DMEM (Invitrogen, Carlsbad, California), 1% Fetal 
Bovine Serum (HyClone, South Logan, Utah) and 0.5% 
penicillin-streptomycin (Invitrogen, Carlsbad, California). 
Cells were trypsinized using TrypLE (GIBCO) and 
resuspended in 1X phosphate-based buffer (PBS). Single-
cell encapsulation was performed through hydrodynamic 
flow controlled by syringe pumps connected to a custom-
fabricated microfluidic device as described previously 
[24]. The single-cell encapsulation, cDNA synthesis 
and amplifications in a nanoliter scale were carried out 
as previously reported [25, 26] Briefly, single cells were 
encapsulated into 600 pico-liter droplets with T-junction 
microfluidic devices or laser cavitation devices [27]. 
These droplets then were manipulated into 10 nano-liter 
Figure 3: Sequential perturbations of cell-cycle-phase-specific genes derived from single-cell transcriptomes of 
patient tumors are applied to treatment. (A) After organizing single-cell transcriptomes by similarity into a sequential order (center-
clustering), expression levels of various cell-cycle-phase-specific genes were plotted to visualize the sequential perturbation of individual 
genes during the cell cycle, a virtual time series. Expression levels were scaled from 0 (undetectable) to 1 (maximum expression). Cell cycle 
phases were defined and colored. As expected, G0/G1-specific genes had higher expression levels in the G0/G1 phase and an S-specific 
gene was mainly expressed within the S phase. G2/M-specific genes had high expression levels in G2/M phase and early G0/G1 phase. 
The sequential expression order suggests that mRNAs of many G2/M-specific genes are not degraded until early in G0/G1 phase after cell 
division. (B, C) Cancer subclones are defined by single-cell transcriptome-clustered cell cycle gene clustering (all cells in a subclone share 
and stay at one cell-cycle stage, which is used to guide treatment. The effective therapeutics drive the number of tumor subclones decrease 
while the number of tumor subclones at relapse increase. 
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reactors for reverse transcription reaction and diluted to 
10 μl. The resulting products were then stored at 
−20° C until they were used for quantitative PCR or 
microarray gene expression profiling (Illumina). Samples 
were prepared for PCR amplification and subsequent 
microarray analysis by adding preamplification master 
mix (Illumina, San Diego, CA) as described previously 
[25]. For comparison, a Single-Cell Preamplification 
Kit (Life-Technologies, CA) was also used for cDNA 
synthesis and subsequently for qPCR verification.
RNA-seq analysis
For RNA-seq samples, trimmed reads were 
mapped onto human genome hg38 using Tophat 2.0.8 as 
implemented in Flow with default settings, using Gencode 
20 annotation (www.gencodegenes.org) as guidance. 
Gencode 20 annotation was used to quantify aligned 
reads to genes/transcripts using the Partek E/M method. 
[28] Read counts per gene in all samples were normalized 
using Upper Quartile normalization [29] and analyzed 
for differential expression using Partek’s Gene Specific 
Analysis method (genes with less than 10 reads in any 
sample were excluded). To generate a list of significantly 
differentially expressed genes among different tissues 
of the same patient, a cutoff of FDR adjusted p < 0.05 
(Poisson regression) and fold change >|2| was applied.
Gene expression normalization and QC
Illumina gene expression data from each sample 
was processed and normalized independently of the other 
tissue/sample types. Analyses were restricted to genes 
significantly expressed in all single HeLa cells and lysates 
at a nominal p-value of 0.01, yielding 2,181 significant 
expression features out of 29,377 annotated probes on 
the array. For assessing agreement between single-cell 
data and lysate data, both were processed using a log 
2 transformation followed by quantile normalization. 
To maximize the signal-to-noise ratio for fine mapping 
of single cells to the cell cycle, a more comprehensive 
approach was taken. The Lumi R package [30] was used 
to employ a variance-stabilizing transformation [31] that 
utilizes technical replicates on the array followed by 
Robust Spline Normalization. Extreme outliers across 
single cells were identified on a probe-by-probe basis and 
the values were set to ‘missing’ if they were more extreme 
than three interquartile ranges away from the first or third 
quartiles. However, no more than one outlier exceeded this 
criterion per probe. Missing data were then inputted using 
a nearest-neighbor averaging method. 
Statistical analysis
In cells that are approximately homogeneous 
with respect to factors other than their cell cycle stages, 
expression of cell cycle-related genes were used to 
determine the position in the cell cycle of each cell in 
relation to others. That is, similarity between cells in 
expression data was used to reflect similarity in cell cycle 
stage. We included in this analysis not only expressed 
genes (as described above), but also genes for which 
existing literature provided us with some evidence of 
their involvement in the cell cycle. Specifically, the 
inclusion criteria required that genes be classified in the 
GO category cell cycle process (GO:0022402). Among 
the many approaches that have been applied to clustering 
genes based on microarray expression patterns, Ray et al. 
[32] applied a traveling salesman problem (TSP) solver 
called Concorde [33] to obtain a one-dimensional ordering 
of genes within clusters. We used Concorde to estimate the 
shortest Hamiltonian path (a variation of the TSP where 
the path does not end at the starting position) based on 
Euclidean distance through the single cells (rather than 
genes). This approach required the construction of an 
adjacency matrix for single cells, which was generated 
using a network-based approach usually applied to the 
identification of co-expressed modules of genes [34].
The cell cycle status of individual cells forms a 
perturbation map, i.e., a diagram of how expression of a 
gene is perturbed as a cell passes through the cell cycle. 
This perturbation map was used with the Self-Organizing 
Maps (SOM) [35] approach to identify clusters of 
genes with the same perturbation signature. Genes with 
perturbation patterns similar to known cell cycle genes 
were inferred to be new candidate cell cycle genes. 
Oncogene profiling database
Multiple cancer profiling databases were used 
for cancer profile analyses, including Cancer Program 
Data Resources | Cancer Program Resource Gateway, 
ONCOMINE (Cancer Microarray Database and Integrated 
Data), Cancer RNA-Seq Nexus (database of phenotype-
specific genome-wide transcriptome profiling of cancerous 
and normal tissue samples), Cancer Gene Expression 
Database (CGED) (database for gene expression profiling 
with accompanying clinical information of human cancer), 
Genomics of Drug Sensitivity in Cancer, Cancer atlas 
(The Human Protein Atlas), The COSMIC (Catalogue 
of Somatic Mutations in Cancer) database and website 
(Sanger Institute), Genomic Profiling in Cancer Patients 
(ClinicalTrials.gov), The Cancer Genome Atlas (TCGA), 
and International Cancer Genome Consortium. The 
relevant biomarkers were used to align with the single cell 
transcriptomes. 
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